Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Federal Trade Commission
Daiichi Sankyo
Healthtrust
Johnson and Johnson
Deloitte
Covington
Harvard Business School

Generated: November 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204370

« Back to Dashboard

NDA 204370 describes VRAYLAR, which is a drug marketed by Allergan Sales Llc and is included in one NDA. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the VRAYLAR profile page.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the cariprazine hydrochloride profile page.
Summary for 204370
Tradename:VRAYLAR
Applicant:Allergan Sales Llc
Ingredient:cariprazine hydrochloride
Patents:2
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 204370
Generic Entry Date for 204370*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 204370
Suppliers and Packaging for NDA: 204370
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370 NDA Allergan, Inc. 61874-115 61874-115-07 7 CAPSULE, GELATIN COATED in 1 BLISTER PACK (61874-115-07)
VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370 NDA Allergan, Inc. 61874-115 61874-115-17 1 BLISTER PACK in 1 CARTON (61874-115-17) > 7 CAPSULE, GELATIN COATED in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 1.5MG BASE
Approval Date:Sep 17, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Nov 9, 2020
Regulatory Exclusivity Use:INFORMATION ADDED TO THE LABELING TO INCLUDE THE EFFICACY AND SAFETY OF CARIPRAZINE RELATIVE TO PLACEBO IN THE PREVENTION OF RELAPSE OF SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA
Regulatory Exclusivity Expiration:Sep 17, 2020
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:➤ Sign UpPatent Expiration:Mar 27, 2027Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Covington
Teva
McKinsey
Harvard Business School
Fuji
Daiichi Sankyo
Healthtrust
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.